Short answer
Viridian Therapeutics, Inc.\DE (VRDN) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $141,000 (up 95.8% year over year) with net income of −$105M.
Q1 2026 key financials · XBRL
- Revenue
- $141,000
- +95.8% YoY
- Net income
- −$105M
- −20.7% YoY
- Operating margin
- -82389.4%
Source: XBRL data from the Viridian Therapeutics, Inc.\DE (VRDN) Q1 2026 10-Q on SEC EDGAR. USD.
Viridian Therapeutics, Inc.\DE Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Elegrobart autoinjector bioequivalence risk, potentially delaying or abandoning its BLA and marketing approval
- Regulatory compliance risk, including FDA post-approval inspections, safety reporting, manufacturing controls, and promotional restrictions
- Clinical-development risk, with regulators potentially requiring more than the planned 300-patient safety databases
- Liquidity risk, with $762.2 million in cash, equivalents, and marketable securities funding planned operations for at least twelve months
- DRI milestone risk, with up to $205 million remaining contingent on clinical, regulatory, or commercial conditions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Viridian Therapeutics, Inc.\DE quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.